Is India’s diagnostics sector poised for a long-term growth upswing? Axis Securities sees opportunity in three stocks
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓Axis Securities says India’s diagnostics sector offers a strong long-term investment opportunity.
- ✓The firm started coverage on Dr Lal PathLabs, Vijaya Diagnostic Centre, and Nephrocare Health Services with buy ratings.
- ✓"We strongly recommend that investors consider BUY positions," the brokerage said, noting that these companies show great growth and quality.
Story at a Glance
- Category
- MARKET
- Reported By
- Livemint
- Reading Speed
- 3 Minute(s)
- Market Focus
- India Economy
Domestic brokerage firm Axis Securities, in its latest report, highlighted that the domestic diagnostics sector offers a compelling multi-year investment opportunity, citing a combination of structural demand visibility, scalable business models, strong cash generation, and improving returns.
The brokerage believes the sector is entering a secular upcycle, with improving utilization, stronger cash conversion, and disciplined expansion creating an attractive combination of growth and quality.
Within this theme, Axis Securities initiated coverage of Dr Lal PathLabs, Vijaya Diagnostic Centre, and Nephrocare Health Services with BUY recommendations, citing potential upside of 20%, 20%, and 21%, respectively.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
Livemint
Read the full, original unfiltered story directly on the publisher's portal.